Saturday 17 October 2026
Export MYGN’s income statement to Excel — free account
Myriad Genetics, Inc.
MYGN Healthcare Diagnostics & Research
Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.98
0.37
−8.51%
Follow MYGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(72.52%) | (68.45%) | (76.73%) | (32.54%) | |
Piotroski F-Score |
4 | 5 | 4 | 5 | |
| (44.27%) | (42.20%) | (47.61%) | (17.11%) | ||
ROIC |
(75.78%) | (71.53%) | (72.93%) | (19.92%) | |
Return on Tangible Assets |
(129.95%) | (116.98%) | (135.97%) | (42.14%) | |
Average Days of Receivables |
52.19 | 51.04 | 54.51 | 49.55 | |
Free Cash Flow per Share |
(0.41) | (0.28) | (0.25) | (0.15) | |
Free Cash Flow |
(38.30) | (25.60) | (23.20) | (14.20) | |
Capital Expenditures |
(36.10) | (27.40) | (25.60) | (21.90) | |
| Other line items | |||||
Cash ROIC |
(6.01%) | (4.02%) | (3.99%) | (2.63%) | |
Accounts Receivable Turnover |
6.77 | 6.97 | 6.79 | 6.54 | |
Accounts Payable Turnover |
7.97 | 7.96 | 8.20 | 8.20 | |
Inventory Turnover |
8.46 | 8.53 | 8.86 | 8.48 | |
Average Days of Payables |
47.45 | 44.17 | 47.79 | 44.14 | |
Days of Inventory on Hand |
47.15 | 45.05 | 40.90 | 44.43 | |
Tax Rate |
(0.06) | (0.07) | 0.00 | 0.01 | |
Research and Development Expense of Revenue |
13.84% | 12.95% | 12.83% | 13.12% | |
Selling, General and Administrative Expense of Revenue |
66.48% | 65.20% | 64.86% | 66.94% | |
Share Based Compensation of Revenue |
5.25% | 4.27% | 3.88% | 3.56% | |
Interest Coverage |
(61.85) | (36.88) | (28.18) | (6.01) | |
Operating CF/Net income |
0.01 | 0.00 | (0.01) | (0.07) | |
Depreciation/Fixed assets |
3.73 | 3.27 | 3.38 | 0.54 | |
Capex/Depreciation |
(0.09) | (0.07) | (0.07) | (0.38) | |
Revenue per Share |
8.86 | 8.90 | 8.85 | 8.51 | |
Operating CF per Share |
(0.02) | 0.02 | 0.03 | 0.08 | |
Capex per Share |
(0.39) | (0.30) | (0.27) | (0.23) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.03 |
Columns are period end dates